AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 263: E274-E281, 1992;
0193-1849/92 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Young, A. A.
Right arrow Articles by Cooper, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, A. A.
Right arrow Articles by Cooper, G. J.

AJP - Endocrinology and Metabolism, Vol 263, Issue 2 E274-E281, Copyright © 1992 by American Physiological Society

ARTICLES

Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists

A. A. Young, B. Gedulin, D. Wolfe-Lopez, H. E. Greene, T. J. Rink and G. J. Cooper
Department of Physiology, Amylin Pharmaceuticals, San Diego, California 92121.

Increasing concentrations of amylin progressively depressed the maximal insulin-stimulated radioglucose incorporation into soleus muscle glycogen, but did not substantively change the EC50 (range 0.78 to 1.52 nM); these findings show noncompetitive, insurmountable antagonism of insulin action by amylin. The results from 36 combinations of different insulin and amylin concentrations were used to construct a response surface that can be used to predict the response for any combination of insulin and amylin concentration. The predicted response to a constant ratio of insulin and amylin concentration is a bell-shaped curve. The experimentally determined response to increasing amounts of an amylin-insulin mixture (molar ratio of 0.14:1, within the range measured for pancreatic secretion and plasma levels) gave a bell-shaped response rather than the sigmoidal response seen with insulin alone. The amylin dose-response relation in the soleus system provides a useful bioassay for amylin agonists. The dose response for highly purified, synthetic human amylin obtained by measuring amylin concentrations by radioimmunoassay in the incubation medium gave an EC50 of 456 pM (+/- 0.18 log units). Human amylin had a potency greater than or equal to that of human insulin in this highly insulin-sensitive preparation.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Clodi, K. Thomaseth, G. Pacini, K. Hermann, A. Kautzky-Willer, W. Waldhausl, R. Prager, and B. Ludvik
Distribution and kinetics of amylin in humans
Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E903 - E908.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. L. Castle, C.-H. Kuo, and J. L. Ivy
Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms
Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E6 - E12.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online